Milestone Pharmaceuticals (NASDAQ:MIST) specializes in the development and commercialization of innovative cardiovascular medicines. Its primary focus is on creating treatments for heart conditions, notably its leading project, etripamil, a novel short-acting calcium channel blocker designed to be self-administered via nasal spray for the treatment of paroxysmal supraventricular tachycardia (PSVT), a condition causing rapid heartbeat. The company aims to transform how heart-related episodes are managed, offering patients rapid relief in non-hospital settings. By advancing its pipeline with etripamil and exploring its potential in other cardiac indications, Milestone is committed to improving the lives of those with cardiovascular diseases, seeking to provide effective patient-centric therapies.